BACKGROUND:Modified vaccinia Ankara (MVA-BN, IMVAMUNE) is emerging as a primary immunogen and as a delivery system to treat or prevent a wide range of diseases. Defining the safety and immunogenicity of MVA-BN in key populations is therefore important. METHODS: We performed a dose-escalation study of MVA-BN administered subcutaneously in 2 doses, one on day 0 and another on day 28. Twenty-four hematopoietic stem cell transplant recipients were enrolled sequentially into the study, and vaccine or placebo was administered under a randomized, double-blind allocation. Ten subjects received vaccine containing10(7) median tissue culture infective doses (TCID50) of MVA-BN, 10 subjects received vaccine containing 10(8) TCID50 of MVA-BN, and 4 subjects received placebo. RESULTS:MVA-BN was generally well tolerated at both doses. No vaccine-related serious adverse events were identified. Transient local reactogenicity was more frequently seen at the higher dose. Neutralizing antibodies (NAb) to Vaccinia virus (VACV) were elicited by both doses of MVA-BN and were greater for the higher dose. Median peak anti-VACV NAb titers were 1:49 in the lower-dose group and 1:118 in the higher-dose group. T-cell immune responses to VACV were detected by an interferon γ enzyme-linked immunosorbent spot assay and were higher in the higher-dose group. CONCLUSIONS:MVA-BN is safe, well tolerated, and immunogenic in HSCT recipients. These data support the use of 10(8) TCID50 of MVA-BN in this population. CLINICAL TRIALS REGISTRATION: NCT00565929.
RCT Entities:
BACKGROUND: Modified vaccinia Ankara (MVA-BN, IMVAMUNE) is emerging as a primary immunogen and as a delivery system to treat or prevent a wide range of diseases. Defining the safety and immunogenicity of MVA-BN in key populations is therefore important. METHODS: We performed a dose-escalation study of MVA-BN administered subcutaneously in 2 doses, one on day 0 and another on day 28. Twenty-four hematopoietic stem cell transplant recipients were enrolled sequentially into the study, and vaccine or placebo was administered under a randomized, double-blind allocation. Ten subjects received vaccine containing 10(7) median tissue culture infective doses (TCID50) of MVA-BN, 10 subjects received vaccine containing 10(8) TCID50 of MVA-BN, and 4 subjects received placebo. RESULTS: MVA-BN was generally well tolerated at both doses. No vaccine-related serious adverse events were identified. Transient local reactogenicity was more frequently seen at the higher dose. Neutralizing antibodies (NAb) to Vaccinia virus (VACV) were elicited by both doses of MVA-BN and were greater for the higher dose. Median peak anti-VACV NAb titers were 1:49 in the lower-dose group and 1:118 in the higher-dose group. T-cell immune responses to VACV were detected by an interferon γ enzyme-linked immunosorbent spot assay and were higher in the higher-dose group. CONCLUSIONS: MVA-BN is safe, well tolerated, and immunogenic in HSCT recipients. These data support the use of 10(8) TCID50 of MVA-BN in this population. CLINICAL TRIALS REGISTRATION: NCT00565929.
Authors: Janie Parrino; Lewis H McCurdy; Brenda D Larkin; Ingelise J Gordon; Steven E Rucker; Mary E Enama; Richard A Koup; Mario Roederer; Robert T Bailer; Zoe Moodie; Lin Gu; Lihan Yan; Barney S Graham Journal: Vaccine Date: 2006-11-07 Impact factor: 3.641
Authors: Ellen Harrer; Michael Bäuerle; Barbara Ferstl; Paul Chaplin; Barbara Petzold; Luis Mateo; Amanda Handley; Maria Tzatzaris; Jens Vollmar; Silke Bergmann; Marion Rittmaier; Kathrin Eismann; Sandra Müller; Joachim R Kalden; Bernd Spriewald; Dieter Willbold; Thomas Harrer Journal: Antivir Ther Date: 2005
Authors: Juliette Morgan; Martha H Roper; Laurence Sperling; Richard A Schieber; James D Heffelfinger; Christine G Casey; Jacqueline W Miller; Scott Santibanez; Barbara Herwaldt; Paige Hightower; Pedro L Moro; Beth F Hibbs; Nancy H Levine; Louisa E Chapman; John Iskander; J Michael Lane; Melinda Wharton; Gina T Mootrey; David L Swerdlow Journal: Clin Infect Dis Date: 2008-03-15 Impact factor: 9.079
Authors: David L Swerdlow; Martha H Roper; Juliette Morgan; Richard A Schieber; Laurence S Sperling; Mercedes M Sniadack; Linda Neff; Jacqueline W Miller; Christine R Curtis; Mona E Marin; John Iskander; Pedro Moro; Paige Hightower; Nancy H Levine; Mary McCauley; James Heffelfinger; Inger Damon; Thomas J Török; Melinda Wharton; Eric E Mast; Gina T Mootrey Journal: Clin Infect Dis Date: 2008-03-15 Impact factor: 9.079
Authors: Christine Meisinger-Henschel; Michaela Schmidt; Susanne Lukassen; Burkhard Linke; Lutz Krause; Sebastian Konietzny; Alexander Goesmann; Paul Howley; Paul Chaplin; Mark Suter; Jürgen Hausmann Journal: J Gen Virol Date: 2007-12 Impact factor: 3.891
Authors: Sharon E Frey; Frances K Newman; Jeffrey S Kennedy; Vera Sobek; Francis A Ennis; Heather Hill; Lihan K Yan; Paul Chaplin; Jens Vollmar; Bernard R Chaitman; Robert B Belshe Journal: Vaccine Date: 2007-10-26 Impact factor: 3.641
Authors: Antonio Cosma; Rashmi Nagaraj; Caroline Staib; Claudia Diemer; Franziska Wopfner; Hermann Schätzl; Dirk H Busch; Gerd Sutter; Frank D Goebel; Volker Erfle Journal: AIDS Res Hum Retroviruses Date: 2007-06 Impact factor: 2.205
Authors: Sharon E Frey; Patricia L Winokur; Heather Hill; Johannes B Goll; Paul Chaplin; Robert B Belshe Journal: Vaccine Date: 2014-03-06 Impact factor: 3.641
Authors: Corinna La Rosa; Jeff Longmate; Joy Martinez; Qiao Zhou; Teodora I Kaltcheva; Weimin Tsai; Jennifer Drake; Mary Carroll; Felix Wussow; Flavia Chiuppesi; Nicola Hardwick; Sanjeet Dadwal; Ibrahim Aldoss; Ryotaro Nakamura; John A Zaia; Don J Diamond Journal: Blood Date: 2016-10-19 Impact factor: 22.113
Authors: Brett W Petersen; Joelle Kabamba; Andrea M McCollum; Robert Shongo Lushima; Emile Okitolonda Wemakoy; Jean-Jacques Muyembe Tamfum; Beatrice Nguete; Christine M Hughes; Benjamin P Monroe; Mary G Reynolds Journal: Antiviral Res Date: 2018-11-14 Impact factor: 5.970
Authors: Sharon E Frey; Jack T Stapleton; Zuhair K Ballas; Wendy L Rasmussen; Thomas M Kaufman; Tammy P Blevins; Travis L Jensen; D Huw Davies; Magdalena Tary-Lehmann; Paul Chaplin; Heather Hill; Johannes B Goll Journal: J Infect Dis Date: 2021-10-28 Impact factor: 7.759